MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymthe.2025.10.007

Медицинская библиотека · Molecular therapy : the journal of the American Society of Gene Therapy · 2025

Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns.

Keselman Dennis J, Small Juliana C, Seneviratne Tiffany, McCague Sarah, Kaschak Taylor L, Yum Sabrina W, O'Brien Andrea, Brandsema John F, Diamond Tamir, Loomes Kathleen M, Lin Kimberly Y, Wittlieb-Weber Carol A, Mayer Oscar H, Daniel Scott G, Waldman Amy T, Samelson-Jones Benjamin J, Matesanz Susan E, George Lindsey A

СтатьяПеревод в очереди

Аннотация

Delandistrogene moxeparvovec is currently the only commercially approved gene therapy for Duchenne muscular dystrophy (DMD). Herein, we report real-world data of 11 ambulatory patients with DMD, ages 4-6, treated with commercial delandistrogene moxeparvovec. Patients were prospectively and uniformly monitored for 1 year post-gene transfer for safety and motor outcomes. Nine patients experienced 15 treatment-related toxicities, and 4 required escalation of corticosteroids. Side effects included gastrointestinal symptoms (n = 7), liver enzyme abnormalities (n = 4), acute liver injury (n = 2), and troponin I elevations (n = 3). In both patients with acute liver injury, troponin I elevations occurred in close temporal association beginning 8-9 weeks post-gene transfer and were responsive to corticosteroids. The clinical courses of these two patients were at least partially consistent with a cellular immune response to the adeno-associated viral vector (AAV) capsid. Troponin I elevations were asymptomatic and without acute functional changes on echocardiogram. The cohort had improvements in year 1 motor function assessments relative to baseline, including a statistically significant median 4-point increase in North Star Ambulatory Assessment score; however, important confounding factors, e.g., baseline corticosteroid use, limit interpretation and will be important to control for in future real-world datasets. Additional follow-up is required to determine long-term safety and motor outcomes, with unclear generalizability of our results.

Для цитирования: Keselman Dennis J, Small Juliana C, Seneviratne Tiffany, McCague Sarah, Kaschak Taylor L, Yum Sabrina W, O'Brien Andrea, Brandsema John F, Diamond Tamir, Loomes Kathleen M, Lin Kimberly Y, Wittlieb-Weber Carol A, Mayer Oscar H, Daniel Scott G, Waldman Amy T, Samelson-Jones Benjamin J, Matesanz Susan E, George Lindsey A. Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns.. Molecular therapy : the journal of the American Society of Gene Therapy. 2025. DOI: 10.1016/j.ymthe.2025.10.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.